1887

Abstract

Hypervirulent strains, most notably BI/NAP1/027, have been increasingly emerging in Western countries as local epidemics. We performed a prospective multicentre observational study from December 2011 to May 2012 to identify recent incidences of toxigenic culture-confirmed hospital-onset infections (CDI) and their associated clinical characteristics in South Korea. Patients suspected of having been suffering from CDI more than 48 h after admission and aged ≥20 years were prospectively enrolled and provided loose stool specimens. Toxigenic culture (anaerobic culture+toxin A/B/binary gene PCR) and PCR ribotyping were performed in one central laboratory. We enrolled 98 toxigenic culture-confirmed CDI-infected patients and 250 toxigenic culture-negative participants from three hospitals. The incidence of toxigenic culture-confirmed hospital-onset CDI cases was 2.7 per 10 000 patient-days. The percentage of severe CDI cases was relatively low at only 3.1 %. UK ribotype 018 was the predominant type (48.1 %). There were no hypervirulent BI/NAP1/027 isolates identified. The independent risk factors for toxigenic culture-confirmed hospital-onset CDI were invasive procedure (odds ratio (OR) 7.3,  = 0.003) and past CDI history within 3 months (OR 28.5,  = 0.003). In conclusion, the incidence and severity of CDI in our study were not higher than reported in Western countries.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.070672-0
2014-11-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/11/1542.html?itemId=/content/journal/jmm/10.1099/jmm.0.070672-0&mimeType=html&fmt=ahah

References

  1. Alonso R., Martín A., Peláez T., Marín M., Rodríguez-Creixéms M., Bouza E.. ( 2005;). Toxigenic status of Clostridium difficile in a large Spanish teaching hospital. . J Med Microbiol 54:, 159–162. [CrossRef][PubMed]
    [Google Scholar]
  2. Anand A., Bashey B., Mir T., Glatt A. E.. ( 1994;). Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. . Am J Gastroenterol 89:, 519–523.[PubMed]
    [Google Scholar]
  3. Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., Petit J. C.. ( 2000;). Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. . J Clin Microbiol 38:, 2386–2388.[PubMed]
    [Google Scholar]
  4. Barbut F., Decré D., Lalande V., Burghoffer B., Noussair L., Gigandon A., Espinasse F., Raskine L., Robert J.. & other authors ( 2005;). Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. . J Med Microbiol 54:, 181–185. [CrossRef][PubMed]
    [Google Scholar]
  5. Bartlett J. G.. ( 1994;). Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. . Clin Infect Dis 18: (Suppl. 4), S265–S272. [CrossRef][PubMed]
    [Google Scholar]
  6. Bartlett J. G., Chang T. W., Gurwith M., Gorbach S. L., Onderdonk A. B.. ( 1978;). Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. . N Engl J Med 298:, 531–534. [CrossRef][PubMed]
    [Google Scholar]
  7. Bauer M. P., Notermans D. W., van Benthem B. H., Brazier J. S., Wilcox M. H., Rupnik M., Monnet D. L., van Dissel J. T., Kuijper E. J..ECDIS Study Group ( 2011;). Clostridium difficile infection in Europe: a hospital-based survey. . Lancet 377:, 63–73. [CrossRef][PubMed]
    [Google Scholar]
  8. Bignardi G. E.. ( 1998;). Risk factors for Clostridium difficile infection. . J Hosp Infect 40:, 1–15. [CrossRef][PubMed]
    [Google Scholar]
  9. Byun T. J., Han D. S., Ahn S. B., Cho H. S., Kim T. Y., Eun C. S., Jeon Y. C., Sohn J. H., Kang J. O.. ( 2009;). [Clinical characteristics and changing epidemiology of Clostridium difficile-associated disease (CDAD)]. . Korean J Gastroenterol 54:, 13–19 (in Korean). [CrossRef][PubMed]
    [Google Scholar]
  10. Clements A. C., Magalhães R. J., Tatem A. J., Paterson D. L., Riley T. V.. ( 2010;). Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. . Lancet Infect Dis 10:, 395–404. [CrossRef][PubMed]
    [Google Scholar]
  11. Crobach M. J., Dekkers O. M., Wilcox M. H., Kuijper E. J.. ( 2009;). European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). . Clin Microbiol Infect 15:, 1053–1066. [CrossRef][PubMed]
    [Google Scholar]
  12. Delmée M., Van Broeck J., Simon A., Janssens M., Avesani V.. ( 2005;). Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. . J Med Microbiol 54:, 187–191. [CrossRef][PubMed]
    [Google Scholar]
  13. Dubberke E. R., Butler A. M., Yokoe D. S., Mayer J., Hota B., Mangino J. E., Khan Y. M., Popovich K. J., Fraser V. J.. ( 2010;). Multicenter study of Clostridium difficile infection rates from 2000 to 2006. . Infect Control Hosp Epidemiol 31:, 1030–1037. [CrossRef][PubMed]
    [Google Scholar]
  14. Freeman J., Bauer M. P., Baines S. D., Corver J., Fawley W. N., Goorhuis B., Kuijper E. J., Wilcox M. H.. ( 2010;). The changing epidemiology of Clostridium difficile infections. . Clin Microbiol Rev 23:, 529–549. [CrossRef][PubMed]
    [Google Scholar]
  15. Gilca R., Hubert B., Fortin E., Gaulin C., Dionne M.. ( 2010;). Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada, 1998-2006. . Infect Control Hosp Epidemiol 31:, 939–947. [CrossRef][PubMed]
    [Google Scholar]
  16. Goorhuis A., Bakker D., Corver J., Debast S. B., Harmanus C., Notermans D. W., Bergwerff A. A., Dekker F. W., Kuijper E. J.. ( 2008;). Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. . Clin Infect Dis 47:, 1162–1170. [CrossRef][PubMed]
    [Google Scholar]
  17. Gravel D., Miller M., Simor A., Taylor G., Gardam M., McGeer A., Hutchinson J., Moore D., Kelly S.. & other authors ( 2009;). Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. . Clin Infect Dis 48:, 568–576. [CrossRef][PubMed]
    [Google Scholar]
  18. Henrich T. J., Krakower D., Bitton A., Yokoe D. S.. ( 2009;). Clinical risk factors for severe Clostridium difficile-associated disease. . Emerg Infect Dis 15:, 415–422. [CrossRef][PubMed]
    [Google Scholar]
  19. Kato H., Kato N., Watanabe K., Iwai N., Nakamura H., Yamamoto T., Suzuki K., Kim S. M., Chong Y., Wasito E. B.. ( 1998;). Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. . J Clin Microbiol 36:, 2178–2182.[PubMed]
    [Google Scholar]
  20. Kim B. N.. ( 2005;). Compliance with an infectious disease specialist’s advisory consultations on targeted antibiotic usage. . J Infect Chemother 11:, 84–88. [CrossRef][PubMed]
    [Google Scholar]
  21. Kim H., Jeong S. H., Roh K. H., Hong S. G., Kim J. W., Shin M. G., Kim M. N., Shin H. B., Uh Y.. & other authors ( 2010;). Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. . Korean J Lab Med 30:, 491–497. [CrossRef][PubMed]
    [Google Scholar]
  22. Kim H., Lee Y., Moon H. W., Lim C. S., Lee K., Chong Y.. ( 2011;). Emergence of Clostridium difficile ribotype 027 in Korea. . Korean J Lab Med 31:, 191–196. [CrossRef][PubMed]
    [Google Scholar]
  23. Kim J., Kang J. O., Kim H., Seo M. R., Choi T. Y., Pai H., Kuijper E. J., Sanders I., Fawley W.. ( 2013a;). Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. . Clin Microbiol Infect 19:, 521–527. [CrossRef][PubMed]
    [Google Scholar]
  24. Kim Y. S., Han D. S., Kim Y. H., Kim W. H., Kim J. S., Kim H. S., Kim H. S., Park Y. S., Song H. J.. & other authors ( 2013b;). Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. . Epidemiol Infect 141:, 189–194. [CrossRef][PubMed]
    [Google Scholar]
  25. Kuehne S. A., Cartman S. T., Heap J. T., Kelly M. L., Cockayne A., Minton N. P.. ( 2010;). The role of toxin A and toxin B in Clostridium difficile infection. . Nature 467:, 711–713. [CrossRef][PubMed]
    [Google Scholar]
  26. Kyne L., Warny M., Qamar A., Kelly C. P.. ( 2000;). Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. . N Engl J Med 342:, 390–397. [CrossRef][PubMed]
    [Google Scholar]
  27. Kyne L., Hamel M. B., Polavaram R., Kelly C. P.. ( 2002;). Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. . Clin Infect Dis 34:, 346–353. [CrossRef][PubMed]
    [Google Scholar]
  28. Lee K., Park K. H., Jeong S. H., Lim H. S., Shin J. H., Yong D., Ha G.-Y., Chong Y..KONSAR ( 2006;). Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance. . Yonsei Med J 47:, 43–54. [CrossRef][PubMed]
    [Google Scholar]
  29. Lee Y. J., Choi M. G., Lim C. H., Jung W. R., Cho H. S., Sung H. Y., Nam K. W., Chang J. H., Cho Y. K.. & other authors ( 2010;). [Change of Clostridium difficile colitis during recent 10 years in Korea]. . Korean J Gastroenterol 55:, 169–174 (in Korean). [CrossRef][PubMed]
    [Google Scholar]
  30. Lee K., Kim M. N., Kim J. S., Hong H. L., Kang J. O., Shin J. H., Park Y. J., Yong D., Jeong S. H., Chong Y..KONSAR Group ( 2011;). Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. . Yonsei Med J 52:, 793–802. [CrossRef][PubMed]
    [Google Scholar]
  31. Lessa F. C., Gould C. V., McDonald L. C.. ( 2012;). Current status of Clostridium difficile infection epidemiology. . Clin Infect Dis 55: (Suppl 2), S65–S70. [CrossRef][PubMed]
    [Google Scholar]
  32. Lo Vecchio A., Zacur G. M.. ( 2012;). Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. . Curr Opin Gastroenterol 28:, 1–9. [CrossRef][PubMed]
    [Google Scholar]
  33. O’Connor J. R., Johnson S., Gerding D. N.. ( 2009;). Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. . Gastroenterology 136:, 1913–1924. [CrossRef][PubMed]
    [Google Scholar]
  34. Patriarchi F., Rolla M., Maccioni F., Menichella A., Scacchi C., Ambrosini A., Costantino A., Quattrucci S.. ( 2011;). Clostridium difficile-related pancolitis in lung-transplanted patients with cystic fibrosis. . Clin Transplant 25:, E46–E51. [CrossRef][PubMed]
    [Google Scholar]
  35. Pépin J., Valiquette L., Alary M. E., Villemure P., Pelletier A., Forget K., Pépin K., Chouinard D.. ( 2004;). Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. . CMAJ 171:, 466–472. [CrossRef][PubMed]
    [Google Scholar]
  36. Peterson L. R., Manson R. U., Paule S. M., Hacek D. M., Robicsek A., Thomson R. B. Jr, Kaul K. L.. ( 2007;). Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. . Clin Infect Dis 45:, 1152–1160. [CrossRef][PubMed]
    [Google Scholar]
  37. Ricciardi R., Rothenberger D. A., Madoff R. D., Baxter N. N.. ( 2007;). Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. . Arch Surg 142:, 624–631, discussion 631. [CrossRef][PubMed]
    [Google Scholar]
  38. Riley T. V., Brazier J. S., Hassan H., Williams K., Phillips K. D.. ( 1987;). Comparison of alcohol shock enrichment and selective enrichment for the isolation of Clostridium difficile. . Epidemiol Infect 99:, 355–359. [CrossRef][PubMed]
    [Google Scholar]
  39. Rubin M. S., Bodenstein L. E., Kent K. C.. ( 1995;). Severe Clostridium difficile colitis. . Dis Colon Rectum 38:, 350–354. [CrossRef][PubMed]
    [Google Scholar]
  40. Safdar N.. ( 2012;). Clostridium difficile: the emerging epidemic. . Mayo Clin Proc 87:, 1037–1039. [CrossRef][PubMed]
    [Google Scholar]
  41. Shin B. M., Kuak E. Y., Yoo H. M., Kim E. C., Lee K., Kang J. O., Whang D. H., Shin J. H.. ( 2008a;). Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000–2005. . J Med Microbiol 57:, 697–701. [CrossRef][PubMed]
    [Google Scholar]
  42. Shin B. M., Kuak E. Y., Yoo S. J., Shin W. C., Yoo H. M.. ( 2008b;). Emerging toxin AB+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. . Diagn Microbiol Infect Dis 60:, 333–337. [CrossRef][PubMed]
    [Google Scholar]
  43. Shin S., Kim M., Kim M., Lim H., Kim H., Lee K., Chong Y.. ( 2012;). Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection. . Annals Lab Med 32:, 355–358. [CrossRef][PubMed]
    [Google Scholar]
  44. Stubbs S. L., Brazier J. S., O’Neill G. L., Duerden B. I.. ( 1999;). PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. . J Clin Microbiol 37:, 461–463.[PubMed]
    [Google Scholar]
  45. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M.. ( 2000;). Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. . FEMS Microbiol Lett 186:, 307–312. [CrossRef][PubMed]
    [Google Scholar]
  46. Tae C. H., Jung S. A., Song H. J., Kim S. E., Choi H. J., Lee M., Hwang Y., Kim H., Lee K.. ( 2009;). The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. . J Korean Med Sci 24:, 520–524. [CrossRef][PubMed]
    [Google Scholar]
  47. Terhes G., Urbán E., Sóki J., Hamid K. A., Nagy E.. ( 2004;). Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. . J Clin Microbiol 42:, 4316–4318. [CrossRef][PubMed]
    [Google Scholar]
  48. Zar F. A., Bakkanagari S. R., Moorthi K. M., Davis M. B.. ( 2007;). A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. . Clin Infect Dis 45:,302–307. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.070672-0
Loading
/content/journal/jmm/10.1099/jmm.0.070672-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error